ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Utility of microRNAs in Exhaled Breath Condensate as Diagnostic Biomarkers to Differentiate Pulmonary Sarcoidosis from Pulmonary Tuberculosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPulmonary sarcoidosis and pulmonary tuberculosis (PTB) are two granulomatous diseases with similar clinical presentations. This study explored the potential of microRNAs (miRNAs) in exhaled breath condensate (EBC) as non-invasive diagnostic biomarkers to distinguish between pulmonary sarcoidosis and PTB. Methods: EBC samples were collected from 46 participants (20 with PTB, 26 with pulmonary sarcoidosis) and 20 healthy controls and miRNA profiling was done. Differentially expressed miRNAs were further validated using qRT-PCR in independent cohorts in EBC (17 PTB, 18 sarcoidosis, and 25 controls) and blood (10 PTB, 10 sarcoidosis, and 10 controls). Results: Initial profiling identified 19 miRNAs differentially expressed between pulmonary sarcoidosis and PTB, one between sarcoidosis and controls, and 22 between PTB and controls. The top five upregulated miRNAs (miR-132, miR-362-5p, miR-181c, miR-181a, and miR-512-3p) and two downregulated miRNAs (miR-454 and miR-139-5p) in sarcoidosis compared to PTB were selected for validation. Validation showed significant downregulation (p value <0.05) of only miR-454 in EBC of sarcoidosis patients compared to PTB patients with an optimal AUC of 0.663. miR-150* discriminated sarcoidosis patients from healthy controls with an AUC of 0.982. When PTB were compared to healthy controls, miR-454 and miR-139-5p were discriminating both groups with AUCs of 0.991 and 0.994 respectively in EBC.
conclusionsThese findings suggest that while miR-454 differentiated pulmonary sarcoidosis from pulmonary tuberculosis, their clinical utility in EBC is limited. Further investigation is needed to explore their diagnostic potential, and to improve diagnostic accuracy in EBC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.